In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|May 14, 2019
Bayer Invests $150 Million to Build a New Cell Culture Technology Center
Author(s)BioPharm International Editors
The new 40,000-ft2 facility will support Bayer's growing biologics portfolio in oncology, cardiology, and additional therapeutic areas.
Advertisement
On May 9, 2019, Bayer announced it will invest $150 million in its pharmaceutical development and manufacturing site in Berkeley, CA, to build a cell culture technology center that will be used to accelerate biological therapy development.
The new center will be built on the company's existing Berkeley campus, home to its recombinant factor VIII manufacturing center that produces hemophilia A treatments. The new 40,000-ft2facility is expected to be ready for clinical production in late 2021 and will support the development of emerging therapies in the company’s biologics portfolio with an emphasis on oncology, cardiology, and additional specialty-care therapeutic areas. Bayer has selected engineering firm Fluor for design and construction and GE Healthcare for the integration of its FlexFactory technology platform, a biomanufacturing platform based on single-use technologies, into the center.
"Bayer's [c]ell [c]enter [t]echnology [c]enter will combine automation, digital capabilities, and single-use bioprocessing technologies to streamline production to allow us to bring new medicines to patients faster," said Judy Chou, PhD, senior vice-president and global head of Bayer Biotech, in a company press release. "We've chosen to partner with Fluor and GE Healthcare on the [c]ell [c]enter [t]echnology [c]enter to leverage their expertise in designing flexible, scalable facilities for the future."
"Fighting cancer on all fronts requires fast and scalable innovation, as well as solutions based on digital insights," said Emmanuel Ligner, president and CEO of GE Healthcare Life Sciences, in the release. “We are delighted to work with Fluor to offer our FlexFactory platform to help Bayer quickly and easily establish development and production capacity in oncology and other therapeutics."
Additionally, the company states that in 2017, it focused its pharmaceutical strategy around key specialty care therapeutic areas and has recently increased its R&D focus. The center will support candidates in the company’s drug pipeline and enable the development of new assets resulting from a range of collaborations.
"Bayer is deeply committed to bringing innovative medicines to market that provide significant patient benefit. This investment allows Bayer to expand our biologics development and launch capabilities, as we advance our R&D programs internally and through strategic collaborations," said Wolfram Carius, PhD, executive vice-president and head of Bayer pharmaceuticals product supply, in the release. "We are especially proud to bring this investment to Berkeley, where Bayer has been for many years, and to the greater San Francisco Bay Area, the birthplace of biotechnology and a global epicenter of drug development innovation."
Source:
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
ImvivaBio’s off-the-shelf CD19/BCMA CAR-T cell therapy CTA313 kept 88% of evaluable patients with refractory lupus in DORIS remission at Month 12, according to longer-term phase 1 data presented at ACR Convergence 2026.
Full phase 3 OASIZ-301 results show both dosing regimens of Amgen’s CD40L antagonist fusion protein dazodalibep reduced systemic disease activity in Sjögren’s disease at Week 48. The every-four-weeks dose also improved patient-reported dryness.
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5